Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid is an experimental small molecule compound with the molecular formula C20H33NO3 and a molecular weight of approximately 335.48 g/mol[1][2][4]. It is classified as a beta amino acid derivative. The compound has not been approved for any therapeutic use in the US or elsewhere and has no known clinical indications or patents[1]. Its mechanism of action involves interaction with serine/threonine-protein phosphatase PP1-alpha catalytic subunit and serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform in humans; however, its pharmacological action remains uncharacterized[1]. There are no reported clinical trials involving this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid.